375 related articles for article (PubMed ID: 11390973)
1. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Ibrahimi OA; Eliseenkova AV; Plotnikov AN; Yu K; Ornitz DM; Mohammadi M
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7182-7. PubMed ID: 11390973
[TBL] [Abstract][Full Text] [Related]
2. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
Anderson J; Burns HD; Enriquez-Harris P; Wilkie AO; Heath JK
Hum Mol Genet; 1998 Sep; 7(9):1475-83. PubMed ID: 9700203
[TBL] [Abstract][Full Text] [Related]
3. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.
Yu K; Herr AB; Waksman G; Ornitz DM
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14536-41. PubMed ID: 11121055
[TBL] [Abstract][Full Text] [Related]
4. Craniosynostosis and related limb anomalies.
Wilkie AO; Oldridge M; Tang Z; Maxson RE
Novartis Found Symp; 2001; 232():122-33; discussion 133-43. PubMed ID: 11277076
[TBL] [Abstract][Full Text] [Related]
5. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
[TBL] [Abstract][Full Text] [Related]
6. Sequence analyses and comparative modeling of fly and worm fibroblast growth factor receptors indicate that the determinants for FGF and heparin binding are retained in evolution.
Nagendra HG; Harrington AE; Harmer NJ; Pellegrini L; Blundell TL; Burke DF
FEBS Lett; 2001 Jul; 501(1):51-8. PubMed ID: 11457455
[TBL] [Abstract][Full Text] [Related]
7. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes.
Britto JA; Moore RL; Evans RD; Hayward RD; Jones BM
J Neurosurg; 2001 Oct; 95(4):660-73. PubMed ID: 11596961
[TBL] [Abstract][Full Text] [Related]
8. Understanding the molecular basis of Apert syndrome.
Ibrahimi OA; Chiu ES; McCarthy JG; Mohammadi M
Plast Reconstr Surg; 2005 Jan; 115(1):264-70. PubMed ID: 15622262
[TBL] [Abstract][Full Text] [Related]
9. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.
Mansukhani A; Bellosta P; Sahni M; Basilico C
J Cell Biol; 2000 Jun; 149(6):1297-308. PubMed ID: 10851026
[TBL] [Abstract][Full Text] [Related]
10. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex.
Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL
Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894
[TBL] [Abstract][Full Text] [Related]
11. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.
Wilkie AO; Slaney SF; Oldridge M; Poole MD; Ashworth GJ; Hockley AD; Hayward RD; David DJ; Pulleyn LJ; Rutland P
Nat Genet; 1995 Feb; 9(2):165-72. PubMed ID: 7719344
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain.
Robertson SC; Meyer AN; Hart KC; Galvin BD; Webster MK; Donoghue DJ
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4567-72. PubMed ID: 9539778
[TBL] [Abstract][Full Text] [Related]
13. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.
Kan SH; Elanko N; Johnson D; Cornejo-Roldan L; Cook J; Reich EW; Tomkins S; Verloes A; Twigg SR; Rannan-Eliya S; McDonald-McGinn DM; Zackai EH; Wall SA; Muenke M; Wilkie AO
Am J Hum Genet; 2002 Feb; 70(2):472-86. PubMed ID: 11781872
[TBL] [Abstract][Full Text] [Related]
14. Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7.
Sher I; Lang T; Lubinsky-Mink S; Kuhn J; Adir N; Chatterjee S; Schomburg D; Ron D
J Biol Chem; 2000 Nov; 275(45):34881-6. PubMed ID: 10950949
[TBL] [Abstract][Full Text] [Related]
15. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity.
Ibrahimi OA; Zhang F; Eliseenkova AV; Linhardt RJ; Mohammadi M
Hum Mol Genet; 2004 Jan; 13(1):69-78. PubMed ID: 14613973
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome.
Cornejo-Roldan LR; Roessler E; Muenke M
Hum Genet; 1999 May; 104(5):425-31. PubMed ID: 10394936
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin.
Pellegrini L; Burke DF; von Delft F; Mulloy B; Blundell TL
Nature; 2000 Oct; 407(6807):1029-34. PubMed ID: 11069186
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia.
Goriely A; McVean GA; van Pelt AM; O'Rourke AW; Wall SA; de Rooij DG; Wilkie AO
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6051-6. PubMed ID: 15840724
[TBL] [Abstract][Full Text] [Related]
19. FGFs, their receptors, and human limb malformations: clinical and molecular correlations.
Wilkie AO; Patey SJ; Kan SH; van den Ouweland AM; Hamel BC
Am J Med Genet; 2002 Oct; 112(3):266-78. PubMed ID: 12357470
[TBL] [Abstract][Full Text] [Related]
20. [Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth factor receptor 2 and rapid mutational analysis in Apert syndrome].
Wada C; Ishigaki M; Toyo-oka Y; Yamabe H; Ohnuki Y; Takada F; Yamazaki Y; Ohtani H
Rinsho Byori; 1996 May; 44(5):435-8. PubMed ID: 8676562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
